RENUIFY

Dead / Abandoned — Abandoned — no statement of use filed (as of 08 Nov 2021)

What this means for you

This application is over — abandoned 08 Nov 2021. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.

Record

Serial number
87838061
Mark type
Stylized text
Filed
16 Mar 2018
Published for opposition
07 Aug 2018
Abandoned
08 Nov 2021
Attorney of record
Monica Riva Talley

Goods and services

  • Class 005 — Pharmaceuticals: Medicated and pharmaceutical preparations, both prescription and over-the-counter, for use in connection with humans and animals, namely, for the treatment of central nervous system disorders, neurologic illnesses, and psychiatric illnesses; pharmaceutical preparations for the treatment of brain ischemia; pharmaceutical preparations for the treatment of brain ischemia, namely, post-stroke recovery, severe intracranial atherosclerosis, carotid endarterectomy, cardiac bypass, cerebral vasculitis, reversible cerebral vasoconstriction syndrome; pharmaceutical preparations for the treatment of brain and cord injuries; pharmaceutical preparations for the treatment of brain and cord injuries, namely, post- intracranial hemorrhage recovery, traumatic brain injury, spinal cord injury; pharmaceutical preparations for the treatment of neurodegenerative diseases; pharmaceutical preparations for the treatment of neurodegenerative diseases, namely, Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), Huntington's disease, Lewy body dementia, frontotemporal dementia, vascular dementia, Parkinson's disease, cognitive impairment of aging, progressive Multiple Sclerosis; pharmaceutical preparations for the treatment of optic and retinal neuropathies; pharmaceutical preparations for the treatment of optic and retinal neuropathies, namely, glaucoma, diabetic retinopathy, ischemic optic and retinal neuropathies; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of pain, namely, opioid sparing analgesia, cancer pain, chronic neuropathic pain, peripheral neuropathy, low back pain in the nature of failed back surgery syndrome, radiculopathy in the nature of sciatica, diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy induced neuropathy and other medication induced neuropathies, complex regional pain syndrome, fibromyalgia, chronic post-operative pain, cluster thoracotomy, phantom limb, stump neuroma; pharmaceutical preparations for the treatment of headache and facial pain, namely, headache, migraine, chronic daily headache, cluster headache, trigeminal neuralgia; pharmaceutical preparations for symptomatic treatments of degenerative diseases; pharmaceutical preparations for symptomatic treatments of degenerative diseases, namely, breath holding in Rett syndrome, dystonias, dysphagia, gait abnormalities, bulbar function in ALS, pseudobulbar affect, levodopa-induced dyskinesias in Parkinson's disease, agitation in AD, disinhibition in dementia; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of epilepsy, namely, precision medicine - adjuvant for genetic epilepsy due to NMDA receptor mutations with hyperactivation; pharmaceutical preparations for the treatment of neuropsychiatric disorders; pharmaceutical preparations for the treatment of neuropsychiatric disorders, namely, treatment resistant depression, Post Traumatic Stress Disorder (PTSD) in the nature of hyperarousal, substance abuse disorders, addiction disorders, Obsessive Compulsive Disorder (OCD), hoarding, trichotillomania, eating disorders, Generalized Anxiety Disorder (GAD), adjustment disorders, panic disorder, major depressive episode, bipolar disorder in the nature of manic and depressive episodes, dysthymia, cyclothymia, psychotic disorders, schizophrenia; pharmaceutical preparations for the treatment of cerebellar disorders; pharmaceutical preparations for the treatment of cerebellar disorders, namely, spinocerebellar ataxia, Friedriech's ataxia, multisystem atrophy, essential tremor; pharmaceutical preparations for the treatment of hearing disorders, tinnitus, delirium, sleep disorders, parasomnias, learning disorders, Attention Deficit Disorder (ADD), Pervasive Developmental Disorders (PDD), Asperger's syndrome, autism, menopausal hot flashes; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancer, namely, monotherapy and adjunctive use

Owner

Prosecution history

  • 08 Nov 2021 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
  • 08 Nov 2021 — ABANDONMENT - NO USE STATEMENT FILED
  • 13 Apr 2021 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
  • 12 Apr 2021 — SOU EXTENSION 5 GRANTED
  • 29 Mar 2021 — SOU EXTENSION 5 FILED
  • 12 Apr 2021 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
  • 29 Mar 2021 — SOU TEAS EXTENSION RECEIVED
  • 24 Sept 2020 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
  • 22 Sept 2020 — SOU EXTENSION 4 GRANTED
  • 22 Sept 2020 — SOU EXTENSION 4 FILED
  • 22 Sept 2020 — SOU TEAS EXTENSION RECEIVED
  • 04 Mar 2020 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
  • 02 Mar 2020 — SOU EXTENSION 3 GRANTED
  • 02 Mar 2020 — SOU EXTENSION 3 FILED
  • 02 Mar 2020 — SOU TEAS EXTENSION RECEIVED

View this trademark record on Marksy